Home Stock Picks Stock Chat Markets Stock Blog Learn to Trade
Stock Newsletters HOT Stock Articles Forex Trading Stock Toolbar Stock Screener Buy Stocks
 
Shortlink

CannaVEST Corp (OTCMKTS:CANV) Makes A Small Step Up

[[tagnumber 0]][[tagnumber 1]]After climbing up the charts in March we saw CannaVEST Corp (OTCMKTS:CANV) get severely corrected. The ticker managed to regain almost all of its previously acquired value in the beginning of last month, but was more hesitant in its second half, settling back a bit.[[tagnumber 2]] [[tagnumber 0]] [[tagnumber 2]] [[tagnumber 0]][[tagnumber 6]]CANV[[tagnumber 7]] recorded four consecutive sessions in the red starting April 28 and sunk to $0.43 per share in the end of Tuesday’s session. Still, the market cap of the company isn’t that big compared to the large numbers contained in its balance sheet. Here is a quick example of [[tagnumber 6]]CANV’s[[tagnumber 7]] financials at the end of the fiscal 2015.[[tagnumber 2]] [[tagnumber 0]] [[tagnumber 2]] [[tagnumber 13]] [[tagnumber 14]]cash: $518 thousand[[tagnumber 15]] [[tagnumber 14]]current assets: $16.6 million[[tagnumber 15]] [[tagnumber 14]]current liabilities: $2.45 million[[tagnumber 15]] [[tagnumber 14]]net sales: $11.53 million[[tagnumber 15]] [[tagnumber 14]]net loss: $12.23 million[[tagnumber 15]] [[tagnumber 24]] [[tagnumber 0]] [[tagnumber 2]] [[tagnumber 0]][[tagnumber 6]]CANV[[tagnumber 7]] is one of the few potstocks that actually had some success in the sector and these numbers are a testament to that. Still, there is the matter of the notes that the company had to issue last year that convert into shares of common stock at hefty discounts to the current price of the stock. We discussed that in more detail in our previous article.[[tagnumber 2]] [[tagnumber 0]] [[tagnumber 2]] [[tagnumber 0]]After the slide that dominated the beginning of this week we finally saw [[tagnumber 6]]CANV[[tagnumber 7]] close in the green yesterday. The company issued a press release and we saw the ticker climb 10.47% in value and closed at $0.475. A total of 638 thousand shares switched hands and generated $304 thousand in daily dollar volume.[[tagnumber 2]] [[tagnumber 0]] [[tagnumber 2]] [[tagnumber 0]]There was some positive movement in today’s trading as well. [[tagnumber 6]]CANV[[tagnumber 7]] reached above the 50 cent per share mark earlier, but is now sitting at $0.49 a pop.[[tagnumber 2]]

Shortlink

Marina Biotech, Inc. (OTCMKTS:MRNA) Surging On News

[[tagnumber 0]][[tagnumber 1]]Marina Biotech, Inc. (OTCMKTS:MRNA) rarely seems some action and it has already been established that it has some liquidity issues. This year wasn’t really good for the company stock, as it was slowly sliding down the charts.[[tagnumber 2]] [[tagnumber 0]] [[tagnumber 2]] [[tagnumber 0]][[tagnumber 6]]MRNA[[tagnumber 7]] certainly got to a level that was low for an OTC biotech company. The company stock’s value dropped below $10 million quite a while back, while the balance sheet didn’t look all that terrible. Here are some of the numbers that were contained in the company’s annual report.[[tagnumber 2]] [[tagnumber 0]] [[tagnumber 2]] [[tagnumber 11]] [[tagnumber 12]]cash: $710 thousand[[tagnumber 13]] [[tagnumber 12]]current assets: $850 thousand[[tagnumber 13]] [[tagnumber 12]]current liabilities: $2.43 million[[tagnumber 13]] [[tagnumber 12]]annual revenues: $680 thousand[[tagnumber 13]] [[tagnumber 12]]loss from operations: $3.98 million[[tagnumber 13]] [[tagnumber 22]] [[tagnumber 0]] [[tagnumber 2]] [[tagnumber 0]]Those numbers aren’t all that bad, but [[tagnumber 6]]MRNA[[tagnumber 7]] still gets really little attention. Yesterday the company made a couple of press releases that shined the spotlight on the ticker. Firstly, they announced that [[tagnumber 6]]MRNA[[tagnumber 7]] has terminated the negotiations for the sale of its nucleic acid therapeutic assets to Microlin Bio.[[tagnumber 2]] [[tagnumber 0]] [[tagnumber 2]] [[tagnumber 0]]Then the company announced that it will acquire the intranasal ketamine program of the infamous Turing Pharmaceuticals AG, the privately held entity that Martin Shkreli founded in February 2015. The company was controversial with its 5,556% hike of the antiparasitic drug Daraprim before Shkreli got arrested by the FBI and charged with securities fraud and had to resign from the positions of CEO.[[tagnumber 2]] [[tagnumber 0]] [[tagnumber 2]] [[tagnumber 0]]The news caused [[tagnumber 6]]MRNA[[tagnumber 7]] to surge 64.47% in value yesterday and we saw the ticker close at 25 cents per share. The volume was more than fifteen times the 30day average and the 3.47 million shares that changed their owners generated $1.13 million in daily trade value.[[tagnumber 2]] [[tagnumber 0]] [[tagnumber 2]] [[tagnumber 0]]After a shaky start of today’s session we see that [[tagnumber 6]]MRNA[[tagnumber 7]] is 6% up as of the writing of this article, but you should still be sure to do your due diligence and weigh out the risks before putting any money on the line.[[tagnumber 2]]

Shortlink

Implant Sciences Corporation (OTCMKTS:IMSC) Gaining More Ground

[[tagnumber 0]][[tagnumber 1]]Implant Sciences Corporations (OTCMKTS:IMSC) has been climbing the charts since it changed its direction back in March. The ticker was sliding for the first half of the year, but as the price began moving in the other direction we also saw an increase in daily volumes.[[tagnumber 2]] [[tagnumber 0]] [[tagnumber 2]] [[tagnumber 0]]The company stock has gained a market value that is more appropriate to the industry that it operates in and the contents of its balance sheet. [[tagnumber 6]]IMSC[[tagnumber 7]] recently filed its financial report for the fiscal 2015 and it contained the following numbers of prime interest.[[tagnumber 2]] [[tagnumber 0]] [[tagnumber 2]] [[tagnumber 11]] [[tagnumber 12]]cash: $776 thousand[[tagnumber 13]] [[tagnumber 12]]current assets: $14.5 million[[tagnumber 13]] [[tagnumber 12]]current liabilities: $96 million[[tagnumber 13]] [[tagnumber 12]]revenues: $10.2 million[[tagnumber 13]] [[tagnumber 12]]net loss: $3.3 million[[tagnumber 13]] [[tagnumber 22]] [[tagnumber 0]] [[tagnumber 2]] [[tagnumber 0]]Apart from the massive amount of liabilities [[tagnumber 6]]IMSC[[tagnumber 7]] is doing fairly well. Still, it did have to negotiate an extension on the maturity date of its debt which was March 31, 2016 and acquire some breathing ground.[[tagnumber 2]] [[tagnumber 0]] [[tagnumber 2]] [[tagnumber 0]]There are speculations that the company might enter into a pretty interesting partnership in the near future or even be acquired by a bigger entity in the sector, which might be one of the things behind the recent climb. Yesterday we saw [[tagnumber 6]]IMSC[[tagnumber 7]] gain another 21.31% in value and close at $0.74 per share, generating $549 thousand in daily dollar volume.[[tagnumber 2]] [[tagnumber 0]] [[tagnumber 2]] [[tagnumber 0]]Today’s session, however, has started differently and we see some hesitation. Only time will tell if this is as high as [[tagnumber 6]]IMSC[[tagnumber 7]] can go and you should be certain to do your due diligence and weigh out the risks before putting any money on the line.[[tagnumber 2]]

© 2013 TheHotPennyStocks.com :: Penny Stocks
Home | Privacy | About Penny Stocks | Our Penny Stock List | Penny Stock Trading Basics | Stock Links | Disclaimer
Search Engine Optimization by Port80Media.com